PODD Insulet Corporation
Best tubeless pump franchise, but competition caps margins near 20%.
The story
Insulet's Omnipod is the leading tubeless insulin delivery platform, benefiting from a durable switch away from traditional pumps. Revenue growth remains strong (~20%+ TTM) but competitive pressure is intensifying with Beta Bionics' FDA approval and margin has stalled below 18% rather than continuing toward 22%. The franchise is real but the path to 22% margins looks longer and less certain than previously assumed.
Trimmed target margin from 22% to 20%: TTM operating margin is 18.1% and has not progressed toward 22% over two years, suggesting competitive and cost realities cap margins lower. Raised terminal growth slightly to 3.5% (still below risk-free) as the installed base and international expansion support durable mid-single-digit volume. Bumped failure probability to 3% reflecting Beta Bionics entry and increasing competitive field. Kept revenue growth, sales-to-capital, beta, and horizon unchanged — the growth story and reinvestment efficiency remain intact.
Value drivers
| Revenue growth (Y1) | 15.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 8y |
| Target operating margin | 20.0% |
| Years to target margin | 8 |
| Sales-to-capital | 1.20 |
| Beta | 1.10 |
| Failure probability | 3.0% |
| Cost of capital (WACC) | 9.4% |
| Terminal WACC | 9.0% |
Valuation bridge
| PV of explicit FCFF | 1.81B |
| PV of terminal value | 6.27B |
| Equity value | 7.61B |
| ÷ shares → per share | $109.76 |
News
bearish -0.30 · 8 articles
- BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status
- 2 S&P 500 Stocks with Impressive Fundamentals and 1 We Turn Down
- Why Pay More For Stryker When BSX Stock Is On Sale?
- Beta Bionics’ insulin patch pump gets FDA nod
- Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
- Artisan Sold Insulet (PODD) Due to Competition Concerns
- Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
- Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 3.51B | 15.0% | 18.4% | 469.20M | 381.69M | 87.51M | 79.96M |
| 2 | 3.98B | 13.4% | 18.6% | 538.66M | 390.87M | 147.80M | 123.40M |
| 3 | 4.45B | 11.7% | 18.8% | 609.36M | 388.58M | 220.78M | 168.44M |
| 4 | 4.89B | 10.1% | 19.1% | 679.08M | 373.22M | 305.87M | 213.23M |
| 5 | 5.31B | 8.4% | 19.3% | 745.38M | 343.80M | 401.59M | 255.82M |
| 6 | 5.67B | 6.8% | 19.5% | 805.64M | 300.11M | 505.52M | 294.26M |
| 7 | 5.96B | 5.1% | 19.8% | 857.24M | 242.89M | 614.35M | 326.77M |
| 8 | 6.17B | 3.5% | 20.0% | 897.78M | 173.80M | 723.98M | 351.86M |
Key risks
- Beta Bionics and emerging competitors erode Omnipod's tubeless differentiation
- Reimbursement pressure from payers on patch pump pricing
- Margin expansion stalls as R&D and SG&A scale with competitive defense
Catalysts
- Omnipod 5 international expansion drives sustained volume growth
- Pharmacy channel penetration improves gross margin mix
- Competitor launch delays or reimbursement setbacks validate moat